Skip to main content

Table 1 Classification of the 4 to 6 micron elutriated mononuclear cell fraction

From: Neurogenic and neuro-protective potential of a novel subpopulation of peripheral blood-derived CD133+ ABCG2+CXCR4+ mesenchymal stem cells: development of autologous cell-based therapeutics for traumatic brain injury

Cell lineage marker

Reagent

Source

Surface antigen

RFI pre-priming, mean +/- SD (% positive)

RFI Post priming, mean +/- SD (% positive)

Leukocyte

BD

CD45 (pan leukocyte)

6.3 +/- 1.1 (0%)

5.4 +/- 0.7 (0%)

 

BD

CD14 (macrophage)

8.3 +/- 2.1 (0%)

6.2 +/- 1.4 (0%)

 

BD

CD3 (T Cell)

5 +/- 0.2 (0%)

6.1+/- 1.6 (0%)

 

BD

T cell receptor (T Cell)

6.3 +/- 1.4 (0%)

4.5 +/- 1.1 (0%)

 

BD

CD19 (B cell)

6.8 +/- 0.7 (0%)

7.4 +/- 1.6 (0%)

 

BD

Immunoglobulin (B Cell)

7.9 +/- 2.3 (0%)

7.6 +/- 3.1 (0%)

 

BD

CD13 (myeloid lineage)

8 +/- 2.4 (0%)

5.5 +/- 2.1 (0%)

Endothelium

BD

CD31

5.9 +/- 2.2 (0%)

6.1 +/- 3.1 (0%)

Fibroblast

BD

CD104a

4.7 +/- 1.1 (0%)

5.1 +/- 2.4 (0%)

 

BD

CD104b

6.2 +/- 2.4 (0%)

7.3 +/- 3.2 (0%)

Chemokine

BD

CXCR4

1236.2 +/- 362.2 (92.1 +/5.8%)

1422.1 +/- 303.2 (86.1 +/- 8.3%)

 

BD

CXCR3

7.2 +/- 3.3 (0%)

6.2 +/- 2.7 (0%)

 

BD

CCR5

8.2 +/- 3.2 (0%)

7.1 +/- 2.7 (0%)

Stem cell

BD, CH

SSEA-1

93 +/- 5.5 (35.2 +/- 5.2%)

5.4 2 +/-0.5 (5.4 +/- 1.6%)**

 

BD, CH

SSEA-4

206.7 +/63 (41.5+/-6.9%)

5.39 +/- 0.7(0%)**

 

BD

CD34

6.1 +/- 2.8 (0%)

7.2 +/- 3.4 (0%)

 

SCT

ABCG2

670.9 +/- 38.7 (84.9 +/- 5.4%)

127.3 +/- 35.4 (31.5 +/- 5.7%)**

 

MIL, BD

CD133

688.8 +/- 63 (95.1+/- 2%)

127.8 +/- 7.4 (39.2 +/- 7.8%)**

 

BD

CD105

1892 +/- 49 (93& +/- 22)

855 +/- 34 (86 +/- 14%)*

 

BD

CD90

1568 +/- 42 (96% +/- 54)

544 +/- 22 (74 +/-11)**

 

BD

CD29

446 +/- 22 (85% +/-16%)

349 +/- 56 (61 +/- 22%)

Human Leukocyte Antigens

BD

MHC Class-1 (human)

38.6 +/- 8 (35+/- 6.2%)

59.5 +/-10 (59.4+/- 7.2%)

 

BD

MHC Class II

11.3 +/- 3.79 (0%)

12.2 +/- 3.7 (0%)

Neuronal Markers

CH

Nestin

11.3 +/- 3.9 (0%)

143.7 +/- 42 (23.1 +/- 4.4%)*

 

CH

Map-1B

11.3 +/- 3.9 (0%)

139.3 +/- 44. 2(16+/- 2.9%)*

 

CH, DAKO

GFAP

4.2 +/- 1.6 (0%)

7.4 +/- 1.7 (0%)

 

CH

Tuj1

2.6 +/- 1.1 (0%)

18.5 +/- 2.4 (3.4+/- 1.6%)

 

CH, CST

TH

2.7 +/- 0.8(0%)

6.2 +/- 2.4 (2.1+/- 0.5%)

  1. Immunocytochemistry was used to examine expression of hematopoietic-, fibroblast-, embryonic- or progenitor cell-associated cluster of differentiation (CD) antigens or markers indicative of neural lineage selection. Staining was evaluated by quantitative flow cytometry using well-defined antibodies. This table shows the occurrence of positive cells (% of cells positive) and relative fluorescent intensity (RFI) of freshly isolated cells before and after RA priming. Statistically significant comparisons for markers include those that decreased (*P < 0.0.001) and increased (**P < 0.05) between isolation and 24 hours post priming. MHC, major histocompatibility complex; CXCR4, CXC chemokine Receptor-4; MAP-1β, microtubule associated protein-1; Tuj1, neuron specific class III β-tubulin; TH, tyrosine hydroxylase; SSEA-4, stage specific embryonic antigen; GFAP, glial fibrillary acidic protein. Reagent sources Becton Dickenson, BD; Chemicon, CH; Stem Cell Technologies, SCT; Cell Signaling Technologies, CST; Miltenyi, MIL.